Response assessment in neuro-oncology criteria: implementation challenges in multicenter neuro-oncology trials.
作者信息
Pope W B, Hessel C
出版信息
AJNR Am J Neuroradiol. 2011 May;32(5):794-7. doi: 10.3174/ajnr.A2582. Epub 2011 Apr 7.
Abstract
摘要
相似文献
1
Response assessment in neuro-oncology criteria: implementation challenges in multicenter neuro-oncology trials.神经肿瘤学标准中的疗效评估：多中心神经肿瘤学试验中的实施挑战
AJNR Am J Neuroradiol. 2011 May;32(5):794-7. doi: 10.3174/ajnr.A2582. Epub 2011 Apr 7.
2
Neuroradiological response criteria for high-grade gliomas.高级别胶质瘤的神经放射学反应标准。
Clin Neuroradiol. 2011 Nov;21(4):199-205. doi: 10.1007/s00062-011-0080-7. Epub 2011 Jun 17.
3
Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas. An intersociety (SINch/AINO/SIN) document.意大利关于低级别胶质瘤的诊断和治疗的共识和建议。一份学会间（SINch/AINO/SIN）文件。
J Neurosurg Sci. 2020 Aug;64(4):313-334. doi: 10.23736/S0390-5616.20.04982-6. Epub 2020 Apr 29.
4
Neuro-oncology in 2013: improving outcome in newly diagnosed malignant glioma.2013年神经肿瘤学：改善新诊断恶性胶质瘤的治疗效果
Nat Rev Neurol. 2014 Feb;10(2):68-70. doi: 10.1038/nrneurol.2013.268. Epub 2014 Jan 14.
5
The Spanish Group of Medical Neuro-Oncology. GENOM.西班牙医学神经肿瘤学组。GENOM。
Clin Transl Oncol. 2006 Jun;8(6):388-90. doi: 10.1007/s12094-006-0191-9.
6
The future of neuro-oncology.神经肿瘤学的未来。
Acta Neurochir (Wien). 2009 Nov;151(11):1343-8. doi: 10.1007/s00701-009-0471-6. Epub 2009 Jul 29.
7
Response assessment in neuro-oncology.神经肿瘤学中的反应评估。
Curr Oncol Rep. 2011 Feb;13(1):50-6. doi: 10.1007/s11912-010-0143-y.
8
Neuro-oncology: diagnosis and management of cerebral gliomas--past, present, and future.神经肿瘤学：脑胶质瘤的诊断与治疗——过去、现在与未来
Neurosurgery. 2000 Jul;47(1):1-8. doi: 10.1097/00006123-200007000-00001.
9
Neuro-oncology in 2015: Progress in glioma diagnosis, classification and treatment.2015年神经肿瘤学：胶质瘤诊断、分类及治疗进展
Nat Rev Neurol. 2016 Feb;12(2):69-70. doi: 10.1038/nrneurol.2015.242. Epub 2016 Jan 18.
10
The emergence of clinical practice parameter guidelines in neuro-oncology: promise of utility tempered with caution.神经肿瘤学临床实践参数指南的出现：效用的前景需谨慎对待。
J Neurooncol. 2008 Sep;89(3):359-62. doi: 10.1007/s11060-008-9619-0.
引用本文的文献
1
Magnetic Resonance Imaging Relaxometry for Glioblastoma Response Assessment During Radiation Therapy on a 0.35 T Magnetic Resonance Imaging Linear Accelerator.0.35T磁共振成像直线加速器在放射治疗期间用于胶质母细胞瘤反应评估的磁共振成像弛豫测量法
Int J Radiat Oncol Biol Phys. 2025 Jul 1;122(3):583-591. doi: 10.1016/j.ijrobp.2025.02.008. Epub 2025 Feb 22.
2
Artificial intelligence in neuro-oncology.神经肿瘤学中的人工智能
Front Neurosci. 2023 Dec 14;17:1217629. doi: 10.3389/fnins.2023.1217629. eCollection 2023.
3
Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment.小儿低级别胶质瘤靶向治疗期间及治疗后的综合反应分析
Neurooncol Adv. 2022 Dec 18;5(1):vdac182. doi: 10.1093/noajnl/vdac182. eCollection 2023 Jan-Dec.
4
Ellipsoid calculations versus manual tumor delineations for glioblastoma tumor volume evaluation.椭球计算与手动肿瘤勾画在胶质母细胞瘤肿瘤体积评估中的比较。
Sci Rep. 2022 Jun 22;12(1):10502. doi: 10.1038/s41598-022-13739-4.
5
The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study.分子性胶质母细胞瘤异柠檬酸脱氢酶野生型的生存结局：一项多中心研究。
J Neurooncol. 2022 Mar;157(1):177-185. doi: 10.1007/s11060-022-03960-6. Epub 2022 Feb 17.
6
Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.采用 IDH 野生型胶质母细胞瘤的非强化病灶类型和对比增强演变模式对神经肿瘤学（RANO）反应评估进行细化。
BMC Cancer. 2021 Jun 1;21(1):654. doi: 10.1186/s12885-021-08414-2.
7
Dynamic Susceptibility Perfusion Imaging for Differentiating Progressive Disease from Pseudoprogression in Diffuse Glioma Molecular Subtypes.动态磁敏感灌注成像用于鉴别弥漫性胶质瘤分子亚型中的疾病进展与假性进展
J Clin Med. 2021 Feb 5;10(4):598. doi: 10.3390/jcm10040598.
8
Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials.放射学阅读范式和中枢影像实验室在神经肿瘤临床试验中的作用。
Neuro Oncol. 2021 Feb 25;23(2):189-198. doi: 10.1093/neuonc/noaa253.
9
T2 mapping of molecular subtypes of WHO grade II/III gliomas.T2 分子亚型图谱在 WHO 分级 II/III 级脑胶质瘤中的应用。
BMC Neurol. 2020 Jan 8;20(1):8. doi: 10.1186/s12883-019-1590-1.
10
Standardized MRI assessment of high-grade glioma response: a review of the essential elements and pitfalls of the RANO criteria.高级别胶质瘤反应的标准化MRI评估：RANO标准的基本要素与陷阱综述
Neurooncol Pract. 2016 Mar;3(1):59-67. doi: 10.1093/nop/npv023. Epub 2015 Jul 12.
本文引用的文献
1
Steroids in neurooncology: actions, indications, side-effects.神经肿瘤学中的类固醇：作用、适应证、副作用。
Curr Opin Neurol. 2010 Dec;23(6):597-602. doi: 10.1097/WCO.0b013e32833e5a5d.
2
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.高级别胶质瘤更新后的反应评估标准：神经肿瘤学工作组的反应评估。
J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15.
3
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.贝伐单抗治疗复发性恶性胶质瘤：疗效、毒性及复发模式
Neurology. 2008 Mar 4;70(10):779-87. doi: 10.1212/01.wnl.0000304121.57857.38.
4
Response criteria for phase II studies of supratentorial malignant glioma.幕上恶性胶质瘤II期研究的反应标准。
J Clin Oncol. 1990 Jul;8(7):1277-80. doi: 10.1200/JCO.1990.8.7.1277.
Zotero 插件